CYTR =MC $10 M -NDA/MAA filing in Q2 /many P3 and P2 program Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTR =MC $10 M -NDA/MAA filing in Q2 /many P3 and P2 program

CYTR 0.0920

0.0%

Oct 5 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: BioHero	1/6/2020 8:44:56 AM
	of 7

Great News out today by drug partner Orphazyme.... Orphazyme announces US Early Access Program for Niemann-Pick disease Type C globenewswire.com The EAP provides a pathway for patients with serious, life-threatening diseases or conditions who lack therapeutic alternatives to gain access to investigational drugs before they are approved. Kim Stratton, Chief Executive Officer, commented, “Orphazyme is deeply committed to providing access to new therapies for people living with rare diseases such as NPC. There are currently no approved products to treat NPC in the US and we are pleased to make arimoclomol, a potential first-in-class innovative oral therapy, available pre-commercially to US patients through this program. We plan to file for approval of arimoclomol in the US in H1 2020”.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next